Evaluation of a dried blood spot assay to measure prenatal screening markers pregnancy-associated plasma protein A and free β-subunit of human chorionic gonadotropin

Clinical Chemistry

Volumn 59, Issue 6, 2013, Pages 968-975

  Cowans, Nicholas J ^a   Suonpaa, Mikko ^b   Kouru, Heikki ^b   Wright, David ^c   Spencer, Kevin ^a  

^a KING GEORGE HOSPITAL   (United Kingdom)

^b PerkinElmer   (Finland)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A;

ADULT; ARTICLE; CLINICAL EVALUATION; DIAGNOSTIC TEST ACCURACY STUDY; DRIED BLOOD SPOT TESTING; FEMALE; FIRST TRIMESTER PREGNANCY; HEMATOCRIT; HUMAN; HUMIDITY; MAJOR CLINICAL STUDY; PRENATAL SCREENING; SERUM; TEMPERATURE;

ADULT; ANEUPLOIDY; CHORIONIC GONADOTROPIN; CHORIONIC GONADOTROPIN, BETA SUBUNIT, HUMAN; DRIED BLOOD SPOT TESTING; FEMALE; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; PREGNANCY-ASSOCIATED PLASMA PROTEIN-A; PRENATAL DIAGNOSIS;

EID: 84878449385     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2012.194894     Document Type: Article

References (32)

1. Wright D, Kagan KO, Molina FS, Gazzoni A, Nicolaides KH. A mixture model of nuchal translucency thickness in screening for chromosomal defects. Ultrasound Obstet Gynecol 2008;31:376-83.
2. Wright D, Spencer K, Kagan KK, Torring N, Petersen OB, Christou A, et al. First-trimester combined screening for trisomy 21 at 7-14 weeks' gestation. Ultrasound Obstet Gynecol 2010;36:404-11.
3. Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 2008;31:618-24.
4. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage firsttrimester screening. Ultrasound Obstet Gynecol 2005;25:221-6. (Pubitemid 40432687)
5. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years prospective experience. BJOG 2003;110:281-6. (Pubitemid 36298912)
6. Spencer K. Evaluation of an assay of the free beta-subunit of choriogonadotropin and its potential value in screening for Down's syndrome. Clin Chem 1991;37:809-14.
7. Cowans NJ, Stamatopoulou A, Hellstrom J, Makela MM, Spencer K. PAPP-A and free betahCG stability in first trimester serum using PerkinElmer AutoDELFIA and DELFIA Xpress systems. Prenat Diagn 2010;30:127-32.
8. Spencer K, Macri JN, Carpenter P, Anderson R, Krantz DA. Stability of intact chorionic gonadotropin (hCG) in serum, liquid whole blood, and dried whole-blood filter-paper spots: impact on screening for Down syndrome by measurement of free beta-hCG subunit. Clin Chem 1993;39:1064-8. (Pubitemid 23166869)
9. Wright D, Abele H, Baker A, Kagan KO. Impact of bias in serum free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A multiples of the median levels on first-rimester screening for trisomy 21. Ultrasound Obstet Gynecol 2011;38:309-13.
10. Pitt JJ. Newborn screening. Clin Biochem Rev 2010;31:57-68.
11. Krantz DA, Hallahan TW, Orlandi F, Buchanan P, Larsen JW Jr, Macri JN. First-trimester Down syndrome screening using dried blood biochemistry and nuchal translucency. Obstet Gynecol 2000;96:207-13. (Pubitemid 30447340)
12. Krantz D, Hallahan T, Ravens R, He K, Cuckle H, Sherwin J, Carmichael J. First trimester Down syndrome screening with dried blood spots using a dual analyte free beta hCG and PAPP-A immunofluorometric assay. Prenat Diagn 2011;31:869-74.
13. Cowans NJ, Stamatopoulou A, Liitti P, Suonpaa M, Spencer K. The stability of free-beta human chorionic gonadotrophin and pregnancy-associated plasma protein-A in first trimester dried blood spots. Prenat Diagn 2011;31:293-8.
14. Lewis SM. Reference ranges and normal values. In: Lewis SM, Bain BJ, Bates I, eds. Dacie and Lewis practical haematology. 9th ed. London: Churchill Livingstone; 2001. p 24.
15. R Development Core Team. R: a language and environment for statistical computing (http://www.R-project.org/). Vienna, Austria: R Foundation for Statistical Computing; 2012.
16. Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, et al. Crystal structure of human chorionic gonadotropin. Nature 1994;369:455-61. (Pubitemid 24210564)
17. WHO International Standard 4th IS Chorionic Gonadotropin, Human NIBSC code: 75/589, Instructions for use. http://www.nibsc.ac.uk/documents/ifu/75-589. pdf (Accessed June 2012).
18. Pinheiro JC, Bates DM. Mixed-effects models in S and S-Plus. New York: Springer; 2000.
19. Spencer K. Aneuploidy screening in the first trimester. Am J Med Genet C Semin Med Genet 2007;145C:18-32. (Pubitemid 46427651)
20. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Health Technol Assess 2003;7:1-77.
21. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002;39:567-76. (Pubitemid 35316289)
22. Spencer K, Cowans NJ, Uldbjerg N, Vereecken A, Torring N. First trimester intact hCG as an early marker of trisomy 21: a promise unrecognised? Prenat Diagn 2008;28:1156-9.
23. Wright D, Spencer K, Nix B. First trimester screening for Down syndrome using free beta hCG, total hCG and PAPP-A: an exploratory study. Prenat Diagn 2007;27:1118-22. (Pubitemid 350250586)
24. Spencer K. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem 2001;38:413-4. (Pubitemid 32626090)
25. Benn PA, Collins R. Evaluation of effect of analytical imprecision in maternal serum screening for Down's syndrome. Ann Clin Biochem 2001;38:28-36. (Pubitemid 32061614)
26. Spencer K. Risk, a QC parameter. DS News 2003;10:30-1.
27. Fraser CG, Petersen PH. Analytical performance characteristics should be judged against objective quality specifications. Clin Chem 1999;45:321-3. (Pubitemid 29114165)
28. Klee GG. Establishment of outcome-related analytic performance goals. Clin Chem 2010;56:714-22.
29. Fraser CG. Biological variation: from principles to practice. Washington, DC: AACC Press; 2001.
30. Spencer K, Cuckle HS. Screening for chromosomal anomalies in the first trimester: does repeat maternal serum screening improve detection rates? Prenat Diagn 2002;22:903-6. (Pubitemid 35175991)
31. Spencer K, Cowans NJ. Analytical goal setting in aneuploidy screening: within person biological variability of first trimester biochemical markers. Prenat Diagn 2013;13:124-9.
32. CDC. Newborn Screening Quality Assurance Program. http://www.cdc.gov/ labstandards/nsqap.html (Accessed June 2012).